SEC Form 4 · accession 0000891293-15-000001
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Corporate Development
Period of report
Jan 5, 2015
Accepted (ET)
Jan 7, 2015 · 7:40 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 5, 2015 | S | 1,000 | $2.34 | D | 404,968 | D | |
| Common Stock | Jan 5, 2015 | S | 300 | $2.345 | D | 404,668 | D | |
| Common Stock | Jan 5, 2015 | S | 100 | $2.35 | D | 404,568 | D | |
| Common Stock | Jan 5, 2015 | S | 1,000 | $2.355 | D | 403,568 | D | |
| Common Stock | Jan 5, 2015 | S | 2,300 | $2.36 | D | 401,268 | D | |
| Common Stock | Jan 5, 2015 | S | 600 | $2.365 | D | 400,668 | D | |
| Common Stock | Jan 5, 2015 | S | 5,700 | $2.37 | D | 394,968 | D | |
| Common Stock | Jan 5, 2015 | S | 1,000 | $2.375 | D | 393,968 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.